OrbiMed’s Tourmaline Bio TRML Stock Holding History

OrbiMed’s Portfolio TRML Stock Details TRML Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-23,600	Closed	-$1.06M	–	146
2022 Q2	$1.06M	Sell	23,600 -1,124	-5%	-$88.7K	0.02%	139
2022 Q1	$2.43M	Hold	24,724	–	–	0.04%	129
2021 Q4	$3.78M	Hold	24,724	–	–	0.05%	140
2021 Q3	$3.35M	Hold	24,724	–	–	0.04%	162
2021 Q2	$3.63M	Buy	+24,724	New	+$3.79M	0.04%	152

Other funds holding TRML

Blackstone Inc New York $32.9B AUM 23.66% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

QUSVM

Qiming U.S. Ventures Management Bellevue, Washington $55.6M AUM 98.09% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return

Bank of Montreal Toronto, Ontario, Canada $304B AUM 35.64% 1-Year Est. Return

OrbiMed's TRML Position: Q3 2022 in Review

OrbiMed sold out of Tourmaline Bio (TRML) in Q3 2022, closing a stake of 23,600 shares — an estimated $1.06M sold.

OrbiMed first reported a position in TRML in Q2 2021 and held it in 5 quarters. The position peaked at $3.78M in Q4 2021. 56 funds tracked by Wall St. Rank hold TRML as of Q3 2022.

OrbiMed reported no remaining Tourmaline Bio position as of Q3 2022 after selling out during the quarter.
OrbiMed sold 23,600 Tourmaline Bio shares in Q3 2022, an estimated $1.06M.
OrbiMed first reported a position in Tourmaline Bio in Q2 2021 and held it in 5 quarters.
OrbiMed's Tourmaline Bio position peaked at $3.78M in Q4 2021.
56 funds tracked by Wall St. Rank held Tourmaline Bio as of Q3 2022.

Based on OrbiMed's 13F filing for Q3 2022, filed 14 Nov 2022.